Congenital dyserythropoietic anemia type 2, also called CDA type II, is a rare inherited blood disease. In this disease, the body makes red blood cells in the wrong way. Many young red blood cells in the bone marrow grow abnormally, so fewer healthy red blood cells reach the blood. This causes anemia, which means the body does not carry enough oxygen. CDA type II is the most common type of congenital dyserythropoietic anemia, and it is usually found in adolescence or early adult life, although it can appear earlier.
Another names for this disease are CDA II, CDA type 2, CDA type II, congenital dyserythropoietic anemia type II, dyserythropoietic anemia congenital type II, and HEMPAS. HEMPAS means hereditary erythroblastic multinuclearity with positive acidified-serum test. This old name was used because many red blood cell precursors in the bone marrow had more than one nucleus, and an older blood test could show a special abnormal reaction.
Congenital dyserythropoietic anemia type 2, often called CDA II, is a rare inherited blood disease in which the bone marrow makes red blood cells in an abnormal way. Many of the young red blood cells do not mature normally, so the body is left with chronic anemia, jaundice, an enlarged spleen, gallstones, and a high risk of iron overload over time. CDA II is most often linked to changes in the SEC23B gene and is usually passed in an autosomal recessive pattern. 1 2 3
In simple words, the main problem in CDA II is ineffective erythropoiesis, which means the body tries to make red blood cells, but many cells are weak, oddly shaped, or die too early before becoming fully useful. Because of that, some people have only mild tiredness, while others may need repeated blood transfusions, iron control, gallbladder treatment, spleen-related care, or in rare severe cases a stem cell transplant evaluation. 1 4 5
Types
The main types of congenital dyserythropoietic anemia are: type I, type II, type III, and type IV. Type I is usually linked with CDAN1 or CDIN1 changes. Type II is linked with SEC23B changes. Type III is linked with KIF23 or RACGAP1 changes. Type IV is linked with KLF1 changes. These types can look similar, but they have different gene causes and different bone marrow changes.
CDA type II is the type in this topic. It is usually inherited in an autosomal recessive way. This means a person usually gets one changed gene copy from the mother and one changed gene copy from the father. Parents often do not have the disease themselves because each parent may carry only one changed copy.
Causes
Strictly speaking, the main proven cause of CDA type II is disease-causing change in the SEC23B gene. But to match your request for 20 causes, the list below gives 20 simple cause-related points, including the direct genetic cause and the disease mechanisms that make the illness happen.
- SEC23B gene mutation means the body carries a harmful change in the SEC23B gene. This is the main known cause of CDA type II.
- Autosomal recessive inheritance means two changed copies are usually needed for disease, one from each parent.
- Carrier parents can pass the changed gene to a child even when the parents look healthy.
- Abnormal protein transport inside cells happens because SEC23B normally helps move proteins to the right place inside cells. When it fails, red blood cell development is disturbed.
- Faulty erythropoiesis means red blood cells are formed in the wrong way in bone marrow. This is the core disease process.
- Abnormal erythroblasts means immature red blood cells become misshapen and do not mature normally.
- Binuclear erythroblasts means many marrow red cell precursors have two nuclei instead of one, showing disturbed cell division.
- Ineffective erythropoiesis means bone marrow tries to make red blood cells but many die before becoming useful cells.
- Early red cell destruction can happen because abnormal red blood cells are removed quickly from the blood.
- Splenic removal of abnormal cells means the spleen filters out damaged red blood cells, which worsens anemia.
- Membrane glycosylation abnormality means some red blood cell membrane proteins are processed in an abnormal way. This is a classic laboratory feature of CDA type II.
- Band 3 protein abnormality is a change seen in one important red blood cell membrane protein, supporting the diagnosis.
- Band 4.5 abnormality is another membrane protein change that can appear in this disease.
- Endoplasmic reticulum membrane problem means abnormal membrane material can collect under the red cell precursor membrane.
- Poor red cell maturation means the cells cannot finish normal growth into healthy mature red blood cells.
- Chronic hemolysis tendency means ongoing destruction of red blood cells may add to the anemia and jaundice.
- Too much iron absorption is not the root cause, but it is part of disease biology and becomes a major problem over time.
- Family history of similar anemia can point to an inherited cause because this condition runs in families.
- Compound heterozygous gene changes means two different harmful SEC23B changes, one on each copy of the gene, can also cause the disease.
- Homozygous gene changes means the same harmful SEC23B change is present on both copies of the gene and can cause CDA type II.
Symptoms
The symptoms can be mild or severe. Some people have only mild anemia for years, while others need more medical care. Below are 15 common symptoms or clinical features in simple words.
- Tiredness happens because the blood carries less oxygen than normal.
- Weakness means the person feels less body strength during normal activity.
- Pale skin can happen in anemia because there are fewer healthy red blood cells.
- Jaundice means yellow skin or yellow eyes from higher bilirubin during red cell breakdown.
- Shortness of breath on activity can happen when oxygen delivery is low.
- Fast heartbeat may appear because the body tries to move more oxygen with less blood capacity.
- Enlarged spleen means the spleen becomes bigger while filtering abnormal blood cells.
- Enlarged liver may happen together with spleen enlargement.
- Gallstones are hard deposits in the gallbladder and are common in CDA type II.
- Belly discomfort can happen from an enlarged spleen, liver, or gallstones.
- Dark urine sometimes may happen when more blood pigment is broken down, though it is not present in every case.
- Poor exercise tolerance means the person gets tired faster than expected when walking or playing.
- Iron overload signs later in life may include liver, heart, or hormone problems because too much iron builds up in the body.
- Growth or school activity limits can happen in children when anemia is stronger, though severity differs from person to person.
- Need for blood transfusion in some patients is more a disease feature than a feeling, but it shows the anemia can become serious in a smaller group of people.
Diagnostic tests
Doctors diagnose CDA type II by combining history, physical examination, blood tests, bone marrow findings, and genetic testing. Some tests look for the disease itself, while other tests look for complications like iron overload or gallstones. I grouped the 20 tests under the categories you asked for. Electrodiagnostic tests are generally not standard for CDA type II, so I explain that clearly below.
Physical exam
- General physical exam means the doctor checks skin color, eye color, heartbeat, breathing, body growth, and signs of anemia or jaundice. This helps the doctor suspect a chronic blood disorder.
- Abdominal exam means the doctor gently feels the belly to see whether the spleen or liver is enlarged. Enlarged organs are common clues in CDA type II.
- Family history review is a practical bedside assessment. The doctor asks whether relatives had anemia, jaundice, gallstones, transfusions, or an inherited blood disease. This is important because CDA type II is genetic.
Manual test
- Peripheral blood smear is a manual microscope test. A lab worker and doctor look at blood cells on a glass slide. In CDA, the smear may show variation in cell size and shape and sometimes nucleated red cells. This helps show that red cell production is abnormal.
- Bone marrow aspirate smear is another manual microscope test. Liquid marrow is taken and looked at under a microscope. In CDA type II, many erythroblasts are binuclear, which is a key finding.
- Bone marrow trephine biopsy review means a small solid marrow sample is examined by a pathologist. It can show erythroid hyperplasia, which means the marrow is trying hard to make red blood cells.
Lab and pathological tests
- Complete blood count, or CBC measures hemoglobin and the number and size of blood cells. It confirms anemia and helps guide the next tests.
- Reticulocyte count measures young red blood cells in the blood. In ineffective erythropoiesis, the result may not rise as much as expected for the amount of anemia.
- Bilirubin test checks whether red blood cell breakdown is increased. High bilirubin can explain jaundice.
- Lactate dehydrogenase, or LDH may rise when red blood cells break down more than usual. It supports hemolysis but is not specific by itself.
- Haptoglobin test may be low in hemolysis because haptoglobin gets used up while binding free hemoglobin.
- Iron studies include serum ferritin, serum iron, and transferrin saturation. These tests look for iron overload, which is common in older patients even without many transfusions.
- Liver function tests help check whether long-term iron overload or other complications are affecting the liver.
- Red cell membrane protein analysis by SDS-PAGE is a special laboratory test. It looks for abnormal movement of membrane proteins such as band 3 and band 4.5. This test is highly sensitive and specific for CDA type II in expert centers.
- Acidified serum lysis test, or Ham/HEMPAS-type test is an older special test. It showed abnormal lysis of the patient’s red cells in acidified serum. Today it is mostly abandoned because it is difficult and less practical.
- SEC23B genetic testing is one of the most important confirmatory tests. It checks for harmful variants in the SEC23B gene and can confirm CDA type II.
- Gene panel or next-generation sequencing may be used when the diagnosis is not clear. It can test SEC23B and other genes that cause similar inherited anemias.
- Electron microscopy of bone marrow cells is not needed in every patient, but it can show special membrane changes under the cell membrane in CDA type II. This can support the diagnosis in difficult cases.
Electrodiagnostic tests
- Electrodiagnostic tests such as nerve conduction studies or electromyography are not standard tests for CDA type II. Doctors usually do not use them to diagnose this blood disease because CDA type II is not mainly a nerve or muscle disorder. If they are used, it is usually to study another problem, not to confirm CDA type II.
Imaging tests
- Imaging tests are used mainly to find complications. Abdominal ultrasound can look for gallstones and enlarged liver or spleen. Liver or heart MRI, especially T2-weighted MRI, can help measure iron overload in organs. These tests do not replace blood tests or genetics, but they are very useful after diagnosis and during follow-up.
Non-Pharmacological Treatments
1) Regular hematology follow-up means seeing a blood specialist at planned intervals so anemia, jaundice, spleen size, growth, and complications are caught early. The purpose is to prevent silent organ damage. The mechanism is simple: repeated review lets doctors act before iron overload, gallstones, or worsening anemia become dangerous. 4 5
2) CBC and hemolysis monitoring includes blood counts, reticulocytes, bilirubin, LDH, and related tests. The purpose is to measure how severe the anemia is and whether red cells are breaking down too fast. The mechanism is ongoing tracking of bone marrow output and red cell destruction. 3) Ferritin and liver monitoring helps detect iron overload early, because people with CDA II can accumulate iron even without many transfusions. 1 4 5
4) MRI iron measurement of the liver and sometimes heart is a key non-drug treatment step because it shows real tissue iron, not just blood iron. The purpose is to guide iron chelation safely. The mechanism is imaging-based measurement of iron deposition inside organs. 5) Ultrasound for gallstones and spleen size helps detect common CDA II complications before emergency pain or infection happens. 1 5
6) Planned red blood cell transfusion support is used in people with severe anemia, growth failure, pregnancy stress, infections, or surgery. The purpose is to improve oxygen delivery and reduce symptoms. The mechanism is immediate replacement of missing healthy red cells. 7) Extended blood matching lowers the chance of transfusion reactions and alloimmunization. 4 5
8) Nutrition review by a dietitian helps avoid extra iron intake when iron is already high and supports folate-rich eating for red cell production. The purpose is safer long-term nutrition. The mechanism is reducing unnecessary iron burden while supporting cell building blocks. 9) Rest-exercise balance means light activity with pacing, which helps fatigue without pushing the body into exhaustion from anemia. 5 1
10) Infection prevention includes good hand hygiene, quick fever review, and extra care after splenectomy. The purpose is to reduce severe infection risk. The mechanism is lowering exposure and acting early. 11) Vaccination review is especially important if the spleen is large, removed, or poorly functioning. 4 6
12) Gallstone surveillance is useful because chronic hemolysis can lead to pigment stones. The purpose is to prevent biliary colic, cholecystitis, or jaundice attacks. The mechanism is finding stones before they block bile flow. 13) Liver and endocrine screening looks for iron-related liver disease, diabetes, delayed puberty, or hormone problems. 1 5
14) Heart monitoring such as ECG or echocardiography may be needed if iron overload becomes significant. The purpose is to catch rhythm problems or heart weakness early. The mechanism is screening organs most harmed by excess iron. 15) Bone health review matters in chronic anemia and chronic disease states, especially if nutrition is poor or activity is limited. 1 5
16) Genetic counseling helps families understand inheritance, carrier risk, and future pregnancy planning. The purpose is informed family decisions. The mechanism is explaining the autosomal recessive pattern and possible testing options. 17) Family screening may identify affected siblings or carriers earlier. 1 2
18) Pregnancy planning with specialists is important because anemia, transfusion need, and iron status may change during pregnancy. The purpose is safer maternal and fetal care. The mechanism is pre-pregnancy correction of avoidable risks. 19) Psychosocial support reduces stress, school/work problems, and treatment burnout. 5 1
20) Stem cell transplant assessment in very severe disease is a non-drug planning step, not a routine treatment for everyone. The purpose is to consider curative replacement of diseased marrow in selected severe cases. The mechanism is replacing the faulty blood-forming system with donor stem cells. 6 4
Drug Treatments
Because CDA II has few directly relevant medicines, I am listing the most important evidence-based medicine options used for iron overload, anemia support, procedure support, or transplant care. These are not all routine for every patient. 4 5
1) Deferasirox is an oral iron chelator used when iron overload becomes important. FDA labeling shows once-daily use, with a common starting dose of 14 mg/kg once daily for transfusional iron overload and 7 mg/kg once daily for some non-transfusion-related iron overload settings. Its purpose is to remove extra body iron. Its mechanism is binding iron so it can be excreted, mainly through stool. Important side effects include kidney injury, liver injury, and gastrointestinal bleeding, so close monitoring is essential. 4 7
2) Deferoxamine is an injectable iron chelator used when oral chelation is not enough or not tolerated. It can be given subcutaneously, intravenously, or intramuscularly. Its purpose is also iron removal. Its mechanism is direct iron binding with urinary and fecal elimination of the iron complex. Side effects can include infusion burden, vision or hearing toxicity with prolonged use, allergy, and local reactions. 4 8
3) Deferiprone is another iron chelator, often considered when other chelation is inadequate or unsuitable. FDA labeling lists a common starting dose of 25 mg/kg three times daily, total 75 mg/kg/day. Its purpose is reducing iron burden. Its mechanism is oral iron binding. Important side effects include neutropenia and agranulocytosis, liver enzyme rise, and zinc deficiency, so regular blood monitoring is required. 4 9
4) Folic acid is often used as supportive therapy in chronic hemolytic states because fast red cell turnover can increase folate need. The purpose is to support DNA synthesis during red blood cell production. The mechanism is replacing a vitamin needed for marrow cell division. Side effects are usually low at standard doses, but folate can hide vitamin B12-related blood findings if used blindly, so it should follow clinician advice. 5 10
5) Leucovorin is not a routine CDA II medicine, but it can be used when folate replacement is needed and oral therapy is not feasible. The purpose is folate rescue or treatment of folate-deficiency megaloblastic anemia. The mechanism is providing an active folate form. A key caution is that it is not proper therapy for vitamin B12 deficiency anemia. 11
6) Acetaminophen may be used for fever or pain around transfusion, viral illness, or recovery from procedures. Its purpose is symptom relief, not disease correction. The mechanism is central pain and fever reduction. A common adult IV dose on FDA labeling is 1,000 mg every 6 hours or 650 mg every 4 hours within daily limits. Major caution is liver toxicity if the dose is too high or multiple acetaminophen products are combined. 12
7) Diphenhydramine may be used before or during transfusion reactions in selected patients. The purpose is to reduce allergic symptoms such as itching, flushing, or hives. The mechanism is H1 antihistamine blockade. Side effects include sleepiness, dry mouth, dizziness, and confusion in some people. It is not needed before every transfusion, but it is sometimes used case by case. 13
8) Penicillin V potassium may be used after splenectomy in selected patients as infection prophylaxis, depending on age, risk, and local practice. The purpose is lowering the risk of severe bacterial infection when spleen protection is reduced. The mechanism is antibacterial activity against susceptible organisms. Main cautions are allergy and antibiotic-associated side effects. 14 6
9) Amoxicillin-clavulanate is not routine daily CDA II therapy, but it may be used when infections complicate severe anemia, surgery, or splenectomy care. The purpose is treatment of bacterial infection. The mechanism is antibiotic plus beta-lactamase inhibition. Side effects include diarrhea, rash, and liver irritation in some people. It should only be used when infection is suspected or confirmed. 15
10) Ursodiol may sometimes be used in hepatobiliary care, but it does not cure the pigment gallstones caused by chronic hemolysis. Its purpose, if chosen by a clinician, is bile-flow support in selected liver or bile situations. The mechanism is altering bile composition. This is an adjunct only, not a main CDA II treatment. 16
Dietary Molecular Supplements
1) Folate-rich supplementation is the most common nutrition support because chronic red cell turnover can increase folate need. 2) Vitamin B12 is useful only when deficiency exists, because low B12 can worsen anemia. 3) Vitamin D may support bone health in people with chronic illness and low outdoor activity. 5
4) Calcium may be considered when intake is low or bone health is a concern. 5) Zinc deserves attention especially if deferiprone is used, because FDA labeling warns about zinc deficiency during therapy. 6) Magnesium may be needed in selected patients with poor intake, diarrhea, or transfusion-related care complexity. 9 5
7) Protein supplements can help undernourished patients maintain muscle and healing. 8) Omega-3 foods or supplements may support general health, though they do not fix the genetic disease. 9) Vitamin C should be used carefully, because high amounts can increase iron absorption in some contexts. 10) Multivitamins without iron may be helpful when diet is poor, but only if they avoid extra iron unless a doctor specifically prescribes iron, which is unusual in CDA II with iron overload risk. 1 5
Drugs Used in Severe Cases, Transplant, or Immune Support
1) Busulfan is a transplant-conditioning drug, not a routine CDA II medicine. FDA labeling describes its use before allogeneic hematopoietic progenitor cell transplantation. The purpose is to clear marrow space for donor cells. The mechanism is marrow-ablating alkylation. Serious risks include myelosuppression, seizures, and hepatic veno-occlusive disease. 17
2) Cyclophosphamide is another transplant-conditioning medicine sometimes used in stem cell transplant protocols. Its purpose is immune suppression and marrow conditioning. The mechanism is alkylating DNA in rapidly dividing cells. Important risks include bone marrow failure, infections, and bladder toxicity. 18
3) Tacrolimus may be used after transplant to reduce graft rejection or graft-versus-host related immune activity, depending on the protocol. The purpose is immune control after donor-cell therapy. The mechanism is calcineurin inhibition that lowers T-cell activation. Important side effects include infection risk, kidney injury, tremor, and high blood pressure. 19
4) Filgrastim can be used after transplant or in selected neutropenia situations to help neutrophil recovery. FDA labeling includes 10 mcg/kg/day after bone marrow transplantation in indicated settings. Its purpose is infection-risk reduction during marrow recovery. The mechanism is stimulation of neutrophil production. 20
5) Methotrexate may be used in some transplant prophylaxis protocols, but it is not standard CDA II disease therapy. The purpose is immune suppression in specific regimens. The mechanism is folate antagonism that limits immune cell proliferation. It can cause mucositis, liver toxicity, marrow suppression, and kidney-related problems. 6) Leucovorin rescue may be paired with methotrexate-based regimens to reduce toxicity. 11 21
Surgeries or Procedures
1) Splenectomy may help selected CDA II patients, especially when the spleen is very large or is worsening anemia by destroying red cells. The reason it is done is to reduce splenic sequestration and improve hemoglobin in some patients. But it raises infection and clotting concerns, so it is never a casual decision. 4 6
2) Cholecystectomy means gallbladder removal when gallstones cause pain, infection, or obstruction. The reason it is done is that chronic hemolysis in CDA II can lead to pigment stones. 3) Central venous access procedures may be needed in heavily transfused or transplant-treated patients for safer repeated access. 1 5
4) Bone marrow aspiration or biopsy is mainly diagnostic, not curative, but it is an important procedure because CDA II classically shows abnormal erythroblasts, including binucleated forms. 5) Hematopoietic stem cell transplantation is the rare major curative procedure for very severe disease when supportive care is not enough. 4 6
Prevention Tips
Keep regular follow-up; check iron early; do not take iron pills unless a doctor clearly says you need them; keep vaccinations up to date; act fast for fever; discuss spleen-related infection risk; monitor liver, heart, and endocrine function when iron is high; use transfusions only when clearly needed; ask for genetic counseling before pregnancy; and keep a written record of ferritin, MRI iron results, transfusions, and surgeries. These steps do not prevent the gene disorder itself, but they can prevent much of the long-term damage. 1 4 5
When to See a Doctor
See a doctor urgently if there is fast worsening tiredness, shortness of breath, chest pain, very dark urine, yellow eyes getting worse, high fever, severe left upper abdominal pain, severe right upper abdominal pain, fainting, swelling, or new palpitations. These can point to severe anemia, infection, gallbladder attack, spleen problems, or iron-related organ injury. 1 5
What to Eat and What to Avoid
Eat folate-rich foods like leafy greens, beans, lentils, citrus, and balanced protein foods; eat enough calories if weight is low; drink enough water; and use a dietitian if appetite is poor. Avoid self-started iron supplements, avoid large amounts of vitamin C tablets unless your doctor agrees, avoid alcohol if liver iron is high, avoid raw-risk foods during immune suppression, and avoid missing meals during periods of weakness. The right diet supports the body, but diet alone cannot cure CDA II. 5 1
FAQs
1) Is CDA II a cancer? No. It is a genetic red blood cell production disorder, not a blood cancer. 1
2) Is CDA II inherited? Yes. It is usually autosomal recessive, meaning both parents are often carriers. 1 2
3) What gene is most often involved? The main gene is SEC23B. 2
4) Can CDA II be mild? Yes. Some people have mild lifelong anemia; others are much more severe. 1
5) Why is iron overload common? Because ineffective erythropoiesis increases iron absorption, and transfusions can add even more iron. 1 5
6) Do all patients need transfusions? No. Transfusions are used only when anemia is severe enough to justify them. 4
7) Is there a cure? Supportive care is standard; stem cell transplant may be curative in rare severe cases. 6
8) Can CDA II cause jaundice? Yes. Chronic red cell breakdown can raise bilirubin and cause yellow eyes or skin. 1
9) Can it cause gallstones? Yes, especially pigment stones related to hemolysis. 1
10) Is splenectomy always helpful? No. Some CDA II patients benefit, but it has risks and needs specialist judgment. 4
11) Should patients take iron pills for anemia? Usually not unless a doctor proves true iron deficiency, because iron overload is common. 1
12) How is iron overload checked best? Ferritin helps, but MRI of liver or heart gives stronger organ information. 5
13) Can children and adults both have CDA II? Yes. It may be recognized in childhood, adolescence, or even adulthood. 1
14) Are there FDA-approved CDA II-specific drugs? I did not find an FDA label for a drug approved specifically to cure CDA II; current care is complication-based. 4 7 8 9
15) What specialist is best? A hematologist, and if disease is severe, a center experienced in rare inherited anemias. 5
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: April 01, 2025.
